1. Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty
- Author
-
Serruys, P.W.J.C. (Patrick), Klein, W.W. (Werner), Tijssen, J.G.P. (Jan), Rutsch, W.R. (Wolfgang), Heyndrickx, G.R. (Guy), Emanuelsson, H.U. (Hakan), Ball, S.G. (Sarah), Decoster, O., Schoeder, E., Liberman, H., Eichhorn, E. (Edwin), Willerson, J.T. (James), Anderson, H.V. (Vernon), Khaja, F., Alexander, R.W. (Robert), Baim, D.S. (Donald), Melkert, R. (Rein), Oene, J.C. van, Gool, R. van, Serruys, P.W.J.C. (Patrick), Klein, W.W. (Werner), Tijssen, J.G.P. (Jan), Rutsch, W.R. (Wolfgang), Heyndrickx, G.R. (Guy), Emanuelsson, H.U. (Hakan), Ball, S.G. (Sarah), Decoster, O., Schoeder, E., Liberman, H., Eichhorn, E. (Edwin), Willerson, J.T. (James), Anderson, H.V. (Vernon), Khaja, F., Alexander, R.W. (Robert), Baim, D.S. (Donald), Melkert, R. (Rein), Oene, J.C. van, and Gool, R. van
- Abstract
BACKGROUND. Ketanserin is a serotonin S2-receptor antagonist that inhibits the platelet activation and vasoconstriction induced by serotonin and also inhibits the mitogenic effect of serotonin on vascular smooth muscle cells. METHODS AND RESULTS. We conducted a randomized, double blind
- Published
- 1993